HORIZON THERAPEUTICS PLC (HZNP) Stock Fundamental Analysis

NASDAQ:HZNP • IE00BQPVQZ61

116.3 USD
+0.05 (+0.04%)
At close: Oct 5, 2023
116.34 USD
+0.04 (+0.03%)
After Hours: 10/5/2023, 8:25:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall HZNP gets a fundamental rating of 6 out of 10. We evaluated HZNP against 521 industry peers in the Biotechnology industry. HZNP is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. HZNP is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • HZNP had positive earnings in the past year.
  • HZNP had a positive operating cash flow in the past year.
HZNP Yearly Net Income VS EBIT VS OCF VS FCFHZNP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 500M 1B

1.2 Ratios

  • HZNP's Return On Assets of 4.71% is amongst the best of the industry. HZNP outperforms 95.21% of its industry peers.
  • Looking at the Return On Equity, with a value of 8.25%, HZNP belongs to the top of the industry, outperforming 95.38% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 5.35%, HZNP belongs to the best of the industry, outperforming 95.87% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for HZNP is significantly below the industry average of 18.69%.
Industry RankSector Rank
ROA 4.71%
ROE 8.25%
ROIC 5.35%
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
HZNP Yearly ROA, ROE, ROICHZNP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 20 -20

1.3 Margins

  • HZNP has a Profit Margin of 12.02%. This is amongst the best in the industry. HZNP outperforms 96.04% of its industry peers.
  • In the last couple of years the Profit Margin of HZNP has declined.
  • The Operating Margin of HZNP (15.58%) is better than 96.53% of its industry peers.
  • HZNP's Operating Margin has improved in the last couple of years.
  • HZNP has a Gross Margin of 75.21%. This is amongst the best in the industry. HZNP outperforms 84.49% of its industry peers.
  • In the last couple of years the Gross Margin of HZNP has grown nicely.
Industry RankSector Rank
OM 15.58%
PM (TTM) 12.02%
GM 75.21%
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
HZNP Yearly Profit, Operating, Gross MarginsHZNP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • HZNP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, HZNP has about the same amount of shares outstanding.
  • HZNP has a better debt/assets ratio than last year.
HZNP Yearly Shares OutstandingHZNP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M
HZNP Yearly Total Debt VS Total AssetsHZNP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B 8B

2.2 Solvency

  • HZNP has an Altman-Z score of 5.10. This indicates that HZNP is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of HZNP (5.10) is better than 81.35% of its industry peers.
  • The Debt to FCF ratio of HZNP is 2.67, which is a good value as it means it would take HZNP, 2.67 years of fcf income to pay off all of its debts.
  • HZNP has a better Debt to FCF ratio (2.67) than 95.54% of its industry peers.
  • HZNP has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
  • HZNP's Debt to Equity ratio of 0.48 is on the low side compared to the rest of the industry. HZNP is outperformed by 74.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 2.67
Altman-Z 5.1
ROIC/WACC0.75
WACC7.16%
HZNP Yearly LT Debt VS Equity VS FCFHZNP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B 4B 5B

2.3 Liquidity

  • HZNP has a Current Ratio of 4.27. This indicates that HZNP is financially healthy and has no problem in meeting its short term obligations.
  • HZNP has a Current ratio of 4.27. This is comparable to the rest of the industry: HZNP outperforms 41.58% of its industry peers.
  • A Quick Ratio of 4.09 indicates that HZNP has no problem at all paying its short term obligations.
  • The Quick ratio of HZNP (4.09) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.27
Quick Ratio 4.09
HZNP Yearly Current Assets VS Current LiabilitesHZNP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • HZNP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.39%.
  • Measured over the past years, HZNP shows a very strong growth in Earnings Per Share. The EPS has been growing by 33.01% on average per year.
  • HZNP shows a decrease in Revenue. In the last year, the revenue decreased by -4.42%.
  • HZNP shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.00% yearly.
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%

3.2 Future

  • HZNP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.92% yearly.
  • The Revenue is expected to grow by 9.94% on average over the next years. This is quite good.
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HZNP Yearly Revenue VS EstimatesHZNP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B
HZNP Yearly EPS VS EstimatesHZNP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 25.90, HZNP can be considered very expensive at the moment.
  • 95.54% of the companies in the same industry are more expensive than HZNP, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of HZNP to the average of the S&P500 Index (27.16), we can say HZNP is valued inline with the index average.
  • Based on the Price/Forward Earnings ratio of 20.14, the valuation of HZNP can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of HZNP indicates a rather cheap valuation: HZNP is cheaper than 96.53% of the companies listed in the same industry.
  • HZNP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.10.
Industry RankSector Rank
PE 25.9
Fwd PE 20.14
HZNP Price Earnings VS Forward Price EarningsHZNP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, HZNP is valued cheaper than 94.88% of the companies in the same industry.
  • 96.37% of the companies in the same industry are more expensive than HZNP, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 27.79
EV/EBITDA 27.94
HZNP Per share dataHZNP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • HZNP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.78
EPS Next 2Y8.89%
EPS Next 3Y11.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for HZNP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

HORIZON THERAPEUTICS PLC

NASDAQ:HZNP (10/5/2023, 8:25:26 PM)

After market: 116.34 +0.04 (+0.03%)

116.3

+0.05 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08
Earnings (Next)N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner Change0%
Market Cap26.63B
Revenue(TTM)3.64B
Net Income(TTM)438.00M
Analysts50.91
Price Target118.83 (2.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.7%
Min EPS beat(2)-27.35%
Max EPS beat(2)13.95%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-27.35%
Max EPS beat(4)21.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.41%
Min Revenue beat(2)-9.59%
Max Revenue beat(2)6.77%
Revenue beat(4)3
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-9.59%
Max Revenue beat(4)6.77%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.27%
Valuation
Industry RankSector Rank
PE 25.9
Fwd PE 20.14
P/S 7.31
P/FCF 27.79
P/OCF 25.59
P/B 5.01
P/tB 26.53
EV/EBITDA 27.94
EPS(TTM)4.49
EY3.86%
EPS(NY)5.77
Fwd EY4.97%
FCF(TTM)4.19
FCFY3.6%
OCF(TTM)4.54
OCFY3.91%
SpS15.92
BVpS23.19
TBVpS4.38
PEG (NY)N/A
PEG (5Y)0.78
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 4.71%
ROE 8.25%
ROCE 6.77%
ROIC 5.35%
ROICexc 7.58%
ROICexgc 27.86%
OM 15.58%
PM (TTM) 12.02%
GM 75.21%
FCFM 26.3%
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
ROICexc(3y)9.75%
ROICexc(5y)6.96%
ROICexgc(3y)39.54%
ROICexgc(5y)N/A
ROCE(3y)8.46%
ROCE(5y)6.07%
ROICexgc growth 3Y27.62%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.99%
ROICexc growth 5YN/A
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
F-Score6
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 2.67
Debt/EBITDA 2.66
Cap/Depr 21.15%
Cap/Sales 2.26%
Interest Coverage 4.07
Cash Conversion 108.78%
Profit Quality 218.81%
Current Ratio 4.27
Quick Ratio 4.09
Altman-Z 5.1
F-Score6
WACC7.16%
ROIC/WACC0.75
Cap/Depr(3y)32.95%
Cap/Depr(5y)21.63%
Cap/Sales(3y)3.95%
Cap/Sales(5y)2.73%
Profit Quality(3y)169.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%
EBIT growth 1Y-37.19%
EBIT growth 3Y74.4%
EBIT growth 5YN/A
EBIT Next Year6.03%
EBIT Next 3Y14.62%
EBIT Next 5Y17.3%
FCF growth 1Y83.52%
FCF growth 3Y42.98%
FCF growth 5Y33.65%
OCF growth 1Y72.19%
OCF growth 3Y43.43%
OCF growth 5Y34.64%

HORIZON THERAPEUTICS PLC / HZNP FAQ

What is the fundamental rating for HZNP stock?

ChartMill assigns a fundamental rating of 6 / 10 to HZNP.


What is the valuation status for HZNP stock?

ChartMill assigns a valuation rating of 5 / 10 to HORIZON THERAPEUTICS PLC (HZNP). This can be considered as Fairly Valued.


How profitable is HORIZON THERAPEUTICS PLC (HZNP) stock?

HORIZON THERAPEUTICS PLC (HZNP) has a profitability rating of 8 / 10.


What are the PE and PB ratios of HORIZON THERAPEUTICS PLC (HZNP) stock?

The Price/Earnings (PE) ratio for HORIZON THERAPEUTICS PLC (HZNP) is 25.9 and the Price/Book (PB) ratio is 5.01.